721 related articles for article (PubMed ID: 17964182)
1. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
2. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
5. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
[TBL] [Abstract][Full Text] [Related]
11. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H
Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
13. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].
Xiong Y; Liang LZ; Zheng M; Wei M; Shen Y
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):29-33. PubMed ID: 17331418
[TBL] [Abstract][Full Text] [Related]
15. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
Geyer H; Schwörer D; Pfleiderer A
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
[TBL] [Abstract][Full Text] [Related]
16. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
18. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations.
Massuger LF; Koper NP; Thomas CM; Dom KE; Schijf CP
Gynecol Oncol; 1997 Mar; 64(3):473-6. PubMed ID: 9062153
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer.
Battaglia F; Scambia G; Panici PB; Castelli M; Ferrandina G; Foti E; Amoroso M; D'Andrea G; Mancuso S
Gynecol Oncol; 1994 May; 53(2):176-82. PubMed ID: 8188076
[TBL] [Abstract][Full Text] [Related]
20. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]